Search research articles
Contact Us
Filters
Showing results (91-100 of 161) with videos related to
Page
of 17
Sort By:
The Oncologist
|
September 20, 2022
Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses
Niven Mehra, Karim Fizazi, Johann S de Bono, et al.
The Lancet. Oncology
|
September 15, 2023
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
Fred Saad, Noel W Clarke, Mototsugu Oya, et al.
Theranostics
|
September 6, 2024
Impact of <i>TP53</i> loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients
Peter H J Slootbeek, María Victoria Luna-Velez, Bastiaan M Privé, et al.
The Lancet. Oncology
|
August 13, 2021
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial
Johann S de Bono, Niven Mehra, Giorgio V Scagliotti, et al.
JCO Precision Oncology
|
May 11, 2026
Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial
Andrew J Armstrong, Fred Saad, Mototsugu Oya, et al.
European Urology
|
March 8, 2021
CD38 in Advanced Prostate Cancers
Christina Guo, Mateus Crespo, Bora Gurel, et al.
BMJ Open
|
August 29, 2023
TripleAiM1: a nationwide registry of de novo metastatic hormone-sensitive prostate cancer with prospective quality-of-life assessment
Tessa van Elst, Jean-Paul van Basten, Pieter van den Berg, et al.
Scientific Reports
|
April 11, 2025
The Conundrum of Treating de novo metastatic Hormone-Sensitive Prostate Cancer
Tessa van Elst, Niven Mehra, Sjaak Bloem, et al.
Cancers
|
December 24, 2021
RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer
Emmy Boerrigter, Guillemette E Benoist, Inge M van Oort, et al.
European Urology Oncology
|
May 18, 2019
Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer
Semini Sumanasuriya, Aurelius Omlin, Andrew Armstrong, et al.
Page
of 17
Search research articles
Search
Showing results (91-100 of 161) with videos related to
Sort By:
Page
of 17
The Oncologist
|
September 20, 2022
Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses
Niven Mehra, Karim Fizazi, Johann S de Bono, et al.
The Lancet. Oncology
|
September 15, 2023
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
Fred Saad, Noel W Clarke, Mototsugu Oya, et al.
Theranostics
|
September 6, 2024
Impact of <i>TP53</i> loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients
Peter H J Slootbeek, María Victoria Luna-Velez, Bastiaan M Privé, et al.
The Lancet. Oncology
|
August 13, 2021
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial
Johann S de Bono, Niven Mehra, Giorgio V Scagliotti, et al.
JCO Precision Oncology
|
May 11, 2026
Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial
Andrew J Armstrong, Fred Saad, Mototsugu Oya, et al.
European Urology
|
March 8, 2021
CD38 in Advanced Prostate Cancers
Christina Guo, Mateus Crespo, Bora Gurel, et al.
BMJ Open
|
August 29, 2023
TripleAiM1: a nationwide registry of de novo metastatic hormone-sensitive prostate cancer with prospective quality-of-life assessment
Tessa van Elst, Jean-Paul van Basten, Pieter van den Berg, et al.
Scientific Reports
|
April 11, 2025
The Conundrum of Treating de novo metastatic Hormone-Sensitive Prostate Cancer
Tessa van Elst, Niven Mehra, Sjaak Bloem, et al.
Cancers
|
December 24, 2021
RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer
Emmy Boerrigter, Guillemette E Benoist, Inge M van Oort, et al.
European Urology Oncology
|
May 18, 2019
Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer
Semini Sumanasuriya, Aurelius Omlin, Andrew Armstrong, et al.
Page
of 17